Healthcare Industry News: Neuropathic Pain
News Release - February 27, 2008
OVATION Appoints Christopher Silber, M.D. as Vice President, Clinical AffairsDEERFIELD, Ill.--(HSMN NewsFeed)--OVATION Pharmaceuticals, Inc. announced today that it has named Christopher Silber, M.D. as Vice President, Clinical Affairs. He will assume his new responsibilities on March 4.
Silber joins OVATION from Takeda where he served as Executive Medical Director and global development team leader for the company’s diabetic neuropathy and Neuropathic Pain clinical programs. Previously he led drug development for Hospira’s critical care and generics portfolios following 13 years at Abbott Laboratories in a variety of clinical research roles, including his roles as Venture Head in analgesia and psychopharmacology where he led overall drug development.
"This is a significant appointment for OVATION at a pivotal time in the advancement of our pipeline," said Jeffrey S. Aronin, OVATION President and Chief Executive Officer. "Chris brings significant drug development expertise, scientific knowledge and world-class clinical planning experience to OVATION,” Aronin added. “This is an exciting time to be part of the OVATION team. We have enormous opportunities to bring forward innovative medicines that address unmet needs of severely ill patients.”
One of Silber’s chief responsibilities is to advance the products in the company’s central nervous system (CNS) pipeline that will enable the company to meet its plans to complete five CNS launches over the next five years.
Silber received his medical degree from the School of Medicine at the State University of New York at Buffalo and his Bachelor of Arts degree from Tufts University. Following training in family medicine at Duke University Medical Center, he assumed his first role in industry with Forest Laboratories as Assistant Medical Director working in the area of Alzheimer’s disease.
About OVATION Pharmaceuticals
OVATION is a fast-growing biopharmaceutical company that develops, manufactures and markets medically necessary therapies to satisfy unmet medical needs for patients with severe illnesses. Headquartered in Deerfield, Ill., with products available in more than 85 countries, OVATION is committed to having a significant impact on patients’ lives through its focus on CNS, hematology/oncology, and hospital-based therapies. The five new launches the company expects over the next five years will be fueled by its late-stage CNS pipeline, which is one of the most robust in the industry. OVATION has been recognized for excellence in the global pharmaceutical and biotechnology industries with the 2006 and 2007 “Pharma Company of the Year” award from Scrip magazine for small to mid-sized enterprises. More information about the company, its products and full prescribing information may be found at www.ovationpharma.com.
Source: OVATION Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.